Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.

OX40 is an immune agonist that induces a strong memory function and directly stimulates T lymphocytes to become highly potent killers of tumor cells.

In a phase I study, patients received a murine version of OX40 on Monday, Wednesday, and Friday for one week only. The murine version of OX40 stimulated a regression of tumors in approximately half of these patients with progressive disease. In many cases, Bradley says, these responses were durable.

This trial demonstrated that OX40 is a highly potent agonist molecule. Bradley says that he is excited for OX40 to be moved into the clinic as a humanized version and single agent. OX40 will also be looked in combination, as preclinical data suggest that OX40 combinations are potent and highly synergistic.

Videos

Edward Bradley, MD, from MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.

Dr. Bradley on OX40 for the Treatment of Cancer

Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmune (the global biologics research and development arm of AstraZeneca), discusses the development of moxetumomab pasudotox.

Moxetumomab pasudotox is a monoclonal antibody made up of an antibody directed at CD22 and Pseudomonas exotoxin. The agent binds to CD22 on the surface of the tumor cell and is incorporated into the cell before the Pseudomonas exotoxin metabolizes, is released, and kills the cell.

In a phase I trial, patients with hairy cell leukemia who had failed previous therapy saw over 90% response rate, with over half being complete responses. Bradley said that the durability of the responses was most striking and that moxetumomab pasudotox was well-tolerated.

Edward Bradley, MD

Articles

Dr. Bradley on OX40 for the Treatment of Cancer

Dr. Bradley Discusses Moxetumomab Pasudotox